Real-Time MV/kV Image Guided Radiation Therapy

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2013 by Stanford University
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01260909
First received: December 14, 2010
Last updated: December 12, 2013
Last verified: December 2013
  Purpose

In current radiation therapy, imaging (typically, cone beam CT imaging or two orthogonal X-ray projection imaging) is done for patient setup before radiation dose delivery. Dose delivery typically takes 2 to 5 minutes depending on the delivery technique used for treatment. A tumor target may change its position during the dose delivery process. The goal of this project is develop a real-time imaging strategy to monitor the tumor position during dose delivery and evaluate its potential clinical impact.


Condition Intervention
Prostate Cancer
Device: Real-time kV/MV Prostate Imaging

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Real-Time MV/kV Image Guided Radiation Therapy

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To verify improved tumor targeting accuracy using IMRT (intensity modulated radiation therapy) and VMAT (volumetric modulated radiation therapy) [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: January 2014
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Real-time kV/MV Prostate Imaging Device: Real-time kV/MV Prostate Imaging
The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
Other Names:
  • Image-guided radiation therapy
  • External beam radiotherapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

prostate cancer patients at Stanford University

Criteria

Inclusion Criteria:

  • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.

Exclusion Criteria:

  • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01260909

Contacts
Contact: Lei Xing (650) 498-7896 lei@stanford.edu

Locations
United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Lei Xing    650-498-7896    lei@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Lei Xing         
Sub-Investigator: Steven L Hancock         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Lei Xing Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01260909     History of Changes
Other Study ID Numbers: PROS0038, SU-12132010-7282, R21CA153587
Study First Received: December 14, 2010
Last Updated: December 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on July 24, 2014